News & Views | Published:

  Heart failure

Implantable cardioverter defibrillators in chronic kidney disease

Nature Reviews Nephrologyvolume 14pages357358 (2018) | Download Citation

A recent observational study reports that implantable cardioverter defibrillators were not associated with improved survival in patients with heart failure, reduced left ventricular ejection fraction and chronic kidney disease. Further studies are needed to identify which of these high-risk patients are most likely to benefit from this potentially life-saving therapy.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E. & Hsu, C. Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351, 1296–1305 (2004).

  2. 2.

    Chertow, G. M., Normand, S.-L. T. & McNeil, B. J. ‘Renalism’: inappropriately low rates of coronary angiography in elderly individuals with renal insufficiency. J Am. Soc. Nephrol. 15, 2462–2468 (2004).

  3. 3.

    Fellstrom, B. C. et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 360, 1395–1407 (2009).

  4. 4.

    Bansal, N. et al. Long-term outcomes associated with implantable cardioverter defibrillator in adults with chronic kidney disease. JAMA Intern. Med. 178, 390–398 (2018).

  5. 5.

    Epstein, A. E. et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities. Circulation 117, e350–e408 (2008).

  6. 6.

    Pun, P. H. et al. Chronic kidney disease is associated with increased risk of sudden cardiac death among patients with coronary artery disease. Kidney Int. 76, 652–658 (2009).

  7. 7.

    Pun, P. H. et al. Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials. Am. J. Kidney Dis. 64, 32–39 (2014).

  8. 8.

    Elming, M. B. et al. Age and outcomes of primary prevention implantable cardioverter-defibrillators in patients with nonischemic systolic heart failure. Circulation 136, 1772–1780 (2017).

  9. 9.

    Goldenberg, I. et al. Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the multicenter automatic defibrillator implantation trial II. Circulation 113, 2810–2817 (2006).

Download references

Acknowledgements

The authors wish to acknowledge helpful discussions with D. M. Charytan (Brigham and Women’s Hospital, Boston, USA) and B. Claggett (Brigham and Women’s Hospital, Boston, USA) regarding this manuscript.

Author information

Affiliations

  1. Renal Division, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA

    • Finnian R. Mc Causland
  2. Harvard Medical School, Boston, MA, USA

    • Finnian R. Mc Causland
    •  & Marc A. Pfeffer
  3. Cardiology Division, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA

    • Marc A. Pfeffer

Authors

  1. Search for Finnian R. Mc Causland in:

  2. Search for Marc A. Pfeffer in:

Competing interests

M.A.P. receives research support from Novartis and serves as a consultant for AstraZeneca, Bayer, Boehringer Ingelheim, DalCor, Genzyme, Gilead, GlaxoSmithKline, Janssen, Lilly, Novartis, Novo Nordisk, Relypsa, Sanofi, Teva and Thrasos. He also has stock options for DalCor. F.R.M. reports no competing interests.

Corresponding author

Correspondence to Marc A. Pfeffer.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/s41581-018-0007-5

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing